Skip to main content
Back
Watch Compare

Connect Biopharma Holdings Ltd

Data quality: 100%
CNTB
NASDAQ Manufacturing Chemicals
$2.83
▲ $0.01 (0.35%)
Mkt Cap: 158.26 M
Price
$2.80
Mkt Cap
158.26 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -51.64 M
Capital intensive — 678.13% of revenue goes to capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-99.75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-87.57%
Below sector avg (-54.01%)
ROIC-71.73%
Net Margin-86687.50%
Op. Margin-90740.63%

Safety

Debt / Equity
N/A
Current Ratio5.48
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-2.85 | -3.77
Below sector avg (-1.49)
P/B Ratio2.86
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -2.9 -1.5
P/B 2.9 1.6
ROE % -87.6 -54.0
Net Margin % -86687.5 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

5 analysts
Buy
Current
$2.83
+179.2%
Target
$7.90
$6.00
$7.50
$10.00
Forecast
Forward P/E -3.77
Forward EPS -$0.82
Est. Revenue 57.04 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.82
-$1.09 – -$0.39
 57.04 M 5
FY2026 -$0.87
-$1.00 – -$0.64
 20.62 M 4

Earnings Surprises

Last 2 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.30 -$0.27 +10.0%
Q32025 -$0.24 -$0.31 -31.9%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -99.75% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 64,000.0 Net Income (TTM) -55.48 M
ROE -87.57% ROA -73.93%
Gross Margin N/A Operating Margin -90740.63%
Net Margin -86687.50% Free Cash Flow (TTM) -51.64 M
ROIC -71.73% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.48
Interest Coverage N/A Asset Turnover 0.00
Working Capital 51.17 M Tangible Book Value 55.32 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.85 Forward P/E -3.77
P/B Ratio 2.86 P/S Ratio 2472.81
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2.77 Fwd Earnings Yield N/A
FCF Yield -32.63%
Market Cap 158.26 M Enterprise Value 120.41 M
Per Share
EPS (Diluted TTM) -1.00 Revenue / Share 0.00
FCF / Share -0.91 OCF / Share -0.91
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 678.13% FCF Conversion 93.08%
SBC-Adj. FCF -55.37 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 64,000.0 26.03 M
Net Income -55.48 M -15.63 M
EPS (Diluted) -1.00 -0.28
Gross Profit — —
Operating Income -58.07 M -22.45 M
EBITDA — —
R&D Expenses 37.80 M 29.26 M
SG&A Expenses — —
D&A 704,000.0 660,000.0
Interest Expense — —
Income Tax 197,000.0 223,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 56.08 M 101.28 M
Total Liabilities 14.10 M 9.12 M
Shareholders' Equity 41.98 M 92.17 M
Total Debt — —
Cash & Equivalents 38.35 M 78.23 M
Current Assets 50.93 M 96.96 M
Current Liabilities 13.61 M 8.46 M